Tuberculosis

Introducing fast and accurate tests where patients seek care

 

Malaria & Acute febrile syndrome (AFS)

Assuring quality of existing rapid tests and developing new tools

Neglected tropical diseases (NTDs)

Contributing to elimination through new and improved tests

Ebola

Partnering to deliver the right tools to the right places

Access

Laboratory strengthening and training

  • 1
  • 2
  • 3
  • 4
  • 5

Latest News

Diagnostics: Fighting outbreaks and improving public health

06 May 2015

Catharina Boehme, FIND CEO, will join a panel of experts from government, civil society, WHO and the private sector who will explore how diagnostics infrastructures, including laboratories and clinics, contribute to the early diagnosis — and appropriate treatment — of diseases in outbreaks, such as Ebola. The diagnostics briefing is part of the 68th World Health Assembly in Geneva and will be take place on Tuesday, May 19th, 2015 from 18:00 to 19:30 at the Palais des Nations, Salle IX.

World Malaria Day 2015 – Message from the CEO

24 April 2015

On World Malaria Day 2015, FIND joins the global malaria community in celebrating the important gains in malaria control of recent years – most importantly, that our collective efforts have reduced by 50% the number of child deaths due to malaria from 2000 to 2013 – while we highlight priority areas for investment and redoubled commitment.

Christian Bréchot, Noel Tata and Sheila Tlou join the FIND Board of Directors

17 April 2015

FIND has announced the addition of three new members to its Board of Directors: Professor Christian Bréchot, the President of the Institut Pasteur, France; Mr Noel Tata, the Managing Director of Tata International Limited and Chairman of Trent Limited; and Professor Sheila Tlou, Director of the UNAIDS Regional Support Team for Eastern and Southern Africa, and a former Minister of Health for Botswana. They join a Board of nine global health and diagnostics industry specialists chaired by Mr Mark Kessel.

Cepheid and FIND announce European approval of Xpert HIV-1 Qual

16 April 2015

Cepheid (Nasdaq: CPHD) and FIND today announced that Xpert® HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert® System, the world’s leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.

right column